Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 5/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13006931 | 0.86 | HTR2C (0.37) | KMOPDCD1CD274P2RX3ACE | |
| SCHEMBL3554123 | 0.82 | S1PR1 (0.41) | KMOMAPTHPGDPRMT1NAAA | |
| SCHEMBL3559574 | 0.81 | OPRM1 (0.37) | KMOMAPTHPGDP2RX3PRSS1 | |
| SCHEMBL3555846 | 0.81 | RECQL (0.41) | KMOMAPTHPGD | |
| SCHEMBL3556463 | 0.80 | S1PR1 (0.38) | KMOCD274MAPTHPGDPRMT1 | |
| SCHEMBL3553651 | 0.80 | FFAR4 (0.43) | KMOPRMT1 | |
| SCHEMBL14423045 | 0.80 | HPGD (0.39) | KMOMAPTHPGDPRMT1NAAA | |
| SCHEMBL3555262 | 0.79 | HDAC4 (0.42) | KMOPRSS1PRMT1NAAADRD2 | |
| SCHEMBL3557933 | 0.77 | KMO (0.37) | KMOPRMT1NOTUMNAAADRD2 | |
| SCHEMBL13006961 | 0.77 | DRD2 (0.42) | KMOPRSS1DRD2DRD3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | claimed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | claimed |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | EPIX PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790707-B2 | S1P receptor modulating compounds and use thereof | EPIX PHARMACEUTICALS INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-2010524-A2 | S1P RECEPTOR MODULATING COMPOUNDS | Epix Delaware, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | AMGEN INC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007109330-A2 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109330-A2 | S1P RECEPTOR MODULATING COMPOUNDS | EPIX DELAWARE, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015177-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR2, S1PR5 | KMO 2321/4885PDCD1 2922/4885CD274 2472/4885 |
| US-20100317649-A1 | S1P Receptor Modulating Compounds and Use Thereof | S1PR1, S1PR2, S1PR5 | KMO 2321/4885PDCD1 2922/4885CD274 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.